United Therapeutics (NASDAQ:UTHR) Stock Unloaded Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently sold shares of United Therapeutics Corporation (NASDAQ:UTHR). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in United Therapeutics stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

United Therapeutics Trading Up 1.8%

Shares of UTHR opened at $485.77 on Wednesday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $486.20. The firm has a fifty day moving average price of $443.02 and a 200-day moving average price of $358.73. The firm has a market capitalization of $20.92 billion, a P/E ratio of 18.41, a P/E/G ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.39 EPS. Analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $400.56, for a total value of $9,012,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 523,935 shares of company stock valued at $226,780,697 over the last 90 days. 10.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc raised its holdings in United Therapeutics by 103.4% in the first quarter. IFP Advisors Inc now owns 1,739 shares of the biotechnology company’s stock worth $536,000 after purchasing an additional 884 shares in the last quarter. Allianz Asset Management GmbH grew its position in shares of United Therapeutics by 96.9% in the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock worth $20,832,000 after buying an additional 33,254 shares during the last quarter. KLP Kapitalforvaltning AS raised its stake in shares of United Therapeutics by 37.6% during the 1st quarter. KLP Kapitalforvaltning AS now owns 59,600 shares of the biotechnology company’s stock worth $18,373,000 after acquiring an additional 16,300 shares in the last quarter. Legato Capital Management LLC purchased a new stake in United Therapeutics during the first quarter valued at approximately $1,512,000. Finally, AE Wealth Management LLC acquired a new stake in United Therapeutics in the first quarter valued at approximately $248,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on UTHR shares. Cantor Fitzgerald increased their price objective on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Oppenheimer upped their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Weiss Ratings reissued a “buy (b-)” rating on shares of United Therapeutics in a research report on Wednesday, November 19th. Bank of America lifted their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Finally, Wells Fargo & Company upped their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $505.00.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.